OGN

SEC source: 0000899243-21-022198 · doc4.xml · derivative · entry 12

Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,862

Underlying: Common Stock · 50,862 shares

Expires 2030-04-30

F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F11 · derivative.exercise_date: 16,954 shares underlying the option are fully vested. The remaining shares vest and become exercisable in two equal installments on May 1, 2022 and May 1, 2023.

SEC source: 0000899243-21-022198 · doc4.xml · derivative · entry 11

Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,646

Underlying: Common Stock · 35,646 shares

Expires 2029-05-02

F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F10 · derivative.exercise_date: 23,763 shares underlying the option are fully vested. The remaining shares vest and become exercisable on May 3, 2022.

SEC source: 0000899243-21-022198 · doc4.xml · derivative · entry 10

Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,215

Underlying: Common Stock · 46,215 shares

Expires 2028-05-03

F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

SEC source: 0000899243-21-022198 · doc4.xml · derivative · entry 9

Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,039

Underlying: Common Stock · 45,039 shares

Expires 2027-05-04

F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

SEC source: 0000899243-21-022198 · doc4.xml · derivative · entry 8

Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,123

Underlying: Common Stock · 26,123 shares

Expires 2026-05-09

F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

SEC source: 0000899243-21-022198 · doc4.xml · derivative · entry 7

Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,828

Underlying: Common Stock · 19,828 shares

Expires 2023-12-31

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock.

F6 · kind: In connection with the Separation, each outstanding Merck performance stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck performance stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F8 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in a single installment on December 31, 2023.

SEC source: 0000899243-21-022198 · doc4.xml · derivative · entry 6

Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,116

Underlying: Common Stock · 9,116 shares

Expires 2022-12-31

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock.

F6 · kind: In connection with the Separation, each outstanding Merck performance stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck performance stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F7 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in a single installment on December 31, 2022.

SEC source: 0000899243-21-022198 · doc4.xml · derivative · entry 5

Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,719

Underlying: Common Stock · 8,719 shares

Expires 2021-12-31

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock.

F6 · kind: In connection with the Separation, each outstanding Merck performance stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck performance stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

SEC source: 0000899243-21-022198 · doc4.xml · derivative · entry 4

Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,957

Underlying: Common Stock · 14,957 shares

Expires 2024-05-04

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock.

F3 · kind: In connection with the Separation, each outstanding Merck restricted stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck restricted stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F5 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in three equal installments on May 4, 2022, May 4, 2023 and May 4, 2024.

SEC source: 0000899243-21-022198 · doc4.xml · derivative · entry 3

Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,336

Underlying: Common Stock · 4,336 shares

Expires 2023-05-01

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock.

F3 · kind: In connection with the Separation, each outstanding Merck restricted stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck restricted stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in two equal installments on May 1, 2022 and May 1, 2023.

SEC source: 0000899243-21-022198 · doc4.xml · derivative · entry 2

Fiedler Susanne · CIK 0001859994 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,579

Underlying: Common Stock · 1,579 shares

Expires 2022-05-03

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock.

F3 · kind: In connection with the Separation, each outstanding Merck restricted stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck restricted stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

SEC source: 0000899243-21-022194 · doc4.xml · derivative · entry 5

DiMarco Kathryn · CIK 0001861045 · Corporate Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,996

Underlying: Common Stock · 28,996 shares

Expires 2031-05-03

F8 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F9 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on May 4, 2022, May 4, 2023 and May 4, 2024.

SEC source: 0000899243-21-022194 · doc4.xml · derivative · entry 4

DiMarco Kathryn · CIK 0001861045 · Corporate Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,957

Underlying: Common Stock · 4,957 shares

Expires 2023-12-31

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock.

F6 · kind: In connection with the Separation, each outstanding Merck performance stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck performance stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F7 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in a single installment on December 31, 2023.

SEC source: 0000899243-21-022194 · doc4.xml · derivative · entry 3

DiMarco Kathryn · CIK 0001861045 · Corporate Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,740

Underlying: Common Stock · 3,740 shares

Expires 2024-05-04

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock.

F3 · kind: In connection with the Separation, each outstanding Merck restricted stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck restricted stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F5 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in three equal installments on May 4, 2022, May 4, 2023 and May 4, 2024.

SEC source: 0000899243-21-022194 · doc4.xml · derivative · entry 2

DiMarco Kathryn · CIK 0001861045 · Corporate Controller

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,609

Underlying: Common Stock · 5,609 shares

Expires 2024-02-09

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock.

F3 · kind: In connection with the Separation, each outstanding Merck restricted stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck restricted stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in three equal installments on February 9, 2022, February 9, 2023 and February 9, 2024.

SEC source: 0000899243-21-022184 · doc4.xml · derivative · entry 4

Telman Deborah H · CIK 0001860008 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 103,095

Underlying: Common Stock · 103,095 shares

Expires 2031-05-03

F7 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F8 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on May 4, 2022, May 4, 2023 and May 4, 2024.

SEC source: 0000899243-21-022184 · doc4.xml · derivative · entry 3

Telman Deborah H · CIK 0001860008 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,624

Underlying: Common Stock · 17,624 shares

Expires 2023-12-31

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon & Co. ("Organon") common stock.

F5 · kind: In connection with the Separation, each outstanding Merck performance stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck performance stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F6 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in a single installment on December 31, 2023.

SEC source: 0000899243-21-022184 · doc4.xml · derivative · entry 2

Telman Deborah H · CIK 0001860008 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,296

Underlying: Common Stock · 13,296 shares

Expires 2024-05-04

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon & Co. ("Organon") common stock.

F2 · kind: In connection with the separation (the "Separation") of Organon from Merck & Co., Inc. ("Merck"), each outstanding Merck restricted stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck restricted stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in three equal installments on May 4, 2022, May 4, 2023 and May 4, 2024.

SEC source: 0000899243-21-022184 · doc4.xml · derivative · entry 1

Telman Deborah H · CIK 0001860008 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,337

Underlying: Common Stock · 19,337 shares

Expires 2023-08-05

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon & Co. ("Organon") common stock.

F2 · kind: In connection with the separation (the "Separation") of Organon from Merck & Co., Inc. ("Merck"), each outstanding Merck restricted stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck restricted stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in three equal installments on August 5, 2021, August 5, 2022 and August 5, 2023.

SEC source: 0000899243-21-022182 · doc4.xml · derivative · entry 4

WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 193,302

Underlying: Common Stock · 193,302 shares

Expires 2031-05-03

F7 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F8 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on May 4, 2022, May 4, 2023 and May 4, 2024.

SEC source: 0000899243-21-022182 · doc4.xml · derivative · entry 3

WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,044

Underlying: Common Stock · 33,044 shares

Expires 2023-12-31

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon & Co. ("Organon") common stock.

F5 · kind: In connection with the Separation, each outstanding Merck performance stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck performance stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F6 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in a single installment on December 31, 2023.

SEC source: 0000899243-21-022182 · doc4.xml · derivative · entry 2

WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 24,930

Underlying: Common Stock · 24,930 shares

Expires 2024-05-04

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon & Co. ("Organon") common stock.

F2 · kind: In connection with the separation (the "Separation") of Organon from Merck & Co., Inc. ("Merck"), each outstanding Merck restricted stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck restricted stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in three equal installments on May 4, 2022, May 4, 2023 and May 4, 2024.

SEC source: 0000899243-21-022182 · doc4.xml · derivative · entry 1

WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,033

Underlying: Common Stock · 67,033 shares

Expires 2023-08-05

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon & Co. ("Organon") common stock.

F2 · kind: In connection with the separation (the "Separation") of Organon from Merck & Co., Inc. ("Merck"), each outstanding Merck restricted stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck restricted stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in three equal installments on August 5, 2021, August 5, 2022 and August 5, 2023.

SEC source: 0000899243-21-022196 · doc4.xml · derivative · entry 4

Stahler Rachel A · CIK 0001679854 · Chief Information Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,876

Underlying: Common Stock · 70,876 shares

Expires 2031-05-03

F7 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F8 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on May 4, 2022, May 4, 2023 and May 4, 2024.

SEC source: 0000899243-21-022196 · doc4.xml · derivative · entry 3

Stahler Rachel A · CIK 0001679854 · Chief Information Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 12,118

Underlying: Common Stock · 12,118 shares

Expires 2023-12-31

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon & Co. ("Organon") common stock.

F5 · kind: In connection with the Separation, each outstanding Merck performance stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck performance stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F6 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in a single installment on December 31, 2023.

SEC source: 0000899243-21-022196 · doc4.xml · derivative · entry 2

Stahler Rachel A · CIK 0001679854 · Chief Information Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,141

Underlying: Common Stock · 9,141 shares

Expires 2024-05-04

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon & Co. ("Organon") common stock.

F2 · kind: In connection with the separation (the "Separation") of Organon from Merck & Co., Inc. ("Merck"), each outstanding Merck restricted stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck restricted stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in three equal installments on May 4, 2022, May 4, 2023 and May 4, 2024.

SEC source: 0000899243-21-022196 · doc4.xml · derivative · entry 1

Stahler Rachel A · CIK 0001679854 · Chief Information Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,675

Underlying: Common Stock · 38,675 shares

Expires 2023-08-05

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon & Co. ("Organon") common stock.

F2 · kind: In connection with the separation (the "Separation") of Organon from Merck & Co., Inc. ("Merck"), each outstanding Merck restricted stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck restricted stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F3 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in three equal installments on August 5, 2021, August 5, 2022 and August 5, 2023.

SEC source: 0000899243-21-022200 · doc4.xml · derivative · entry 13

Milligan Sandra · CIK 0001859810 · Head of Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 115,980

Underlying: Common Stock · 115,980 shares

Expires 2031-05-03

F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F12 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on May 4, 2022, May 4, 2023 and May 4, 2024.

SEC source: 0000899243-21-022200 · doc4.xml · derivative · entry 12

Milligan Sandra · CIK 0001859810 · Head of Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,503

Underlying: Common Stock · 44,503 shares

Expires 2030-04-30

F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F11 · derivative.exercise_date: 14,834 shares underlying the option are fully vested. The remaining shares vest and become exercisable in two equal installments on May 1, 2022 and May 1, 2023.

SEC source: 0000899243-21-022200 · doc4.xml · derivative · entry 11

Milligan Sandra · CIK 0001859810 · Head of Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 41,588

Underlying: Common Stock · 41,588 shares

Expires 2029-05-02

F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F10 · derivative.exercise_date: 27,724 shares underlying the option are fully vested. The remaining shares vest and become exercisable on May 3, 2022.

SEC source: 0000899243-21-022200 · doc4.xml · derivative · entry 10

Milligan Sandra · CIK 0001859810 · Head of Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,919

Underlying: Common Stock · 53,919 shares

Expires 2028-05-03

F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

SEC source: 0000899243-21-022200 · doc4.xml · derivative · entry 9

Milligan Sandra · CIK 0001859810 · Head of Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,054

Underlying: Common Stock · 63,054 shares

Expires 2027-05-04

F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

SEC source: 0000899243-21-022200 · doc4.xml · derivative · entry 8

Milligan Sandra · CIK 0001859810 · Head of Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,931

Underlying: Common Stock · 48,931 shares

Expires 2026-05-09

F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

SEC source: 0000899243-21-022200 · doc4.xml · derivative · entry 7

Milligan Sandra · CIK 0001859810 · Head of Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,828

Underlying: Common Stock · 19,828 shares

Expires 2023-12-31

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock.

F6 · kind: In connection with the Separation, each outstanding Merck performance stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck performance stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F8 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in a single installment on December 31, 2023.

SEC source: 0000899243-21-022200 · doc4.xml · derivative · entry 6

Milligan Sandra · CIK 0001859810 · Head of Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,975

Underlying: Common Stock · 7,975 shares

Expires 2022-12-31

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock.

F6 · kind: In connection with the Separation, each outstanding Merck performance stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck performance stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F7 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in a single installment on December 31, 2022.

SEC source: 0000899243-21-022200 · doc4.xml · derivative · entry 5

Milligan Sandra · CIK 0001859810 · Head of Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,170

Underlying: Common Stock · 10,170 shares

Expires 2021-12-31

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock.

F6 · kind: In connection with the Separation, each outstanding Merck performance stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck performance stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

SEC source: 0000899243-21-022200 · doc4.xml · derivative · entry 4

Milligan Sandra · CIK 0001859810 · Head of Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,957

Underlying: Common Stock · 14,957 shares

Expires 2024-05-04

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock.

F3 · kind: In connection with the Separation, each outstanding Merck restricted stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck restricted stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F5 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in three equal installments on May 4, 2022, May 4, 2023 and May 4, 2024.

SEC source: 0000899243-21-022200 · doc4.xml · derivative · entry 3

Milligan Sandra · CIK 0001859810 · Head of Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,795

Underlying: Common Stock · 3,795 shares

Expires 2023-05-01

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock.

F3 · kind: In connection with the Separation, each outstanding Merck restricted stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck restricted stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in two equal installments on May 1, 2022 and May 1, 2023.

SEC source: 0000899243-21-022200 · doc4.xml · derivative · entry 2

Milligan Sandra · CIK 0001859810 · Head of Research & Development

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,842

Underlying: Common Stock · 1,842 shares

Expires 2022-05-03

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock.

F3 · kind: In connection with the Separation, each outstanding Merck restricted stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck restricted stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

SEC source: 0000899243-21-022199 · doc4.xml · derivative · entry 10

Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,433

Underlying: Common Stock · 64,433 shares

Expires 2031-05-03

F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F12 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on May 4, 2022, May 4, 2023 and May 4, 2024.

SEC source: 0000899243-21-022199 · doc4.xml · derivative · entry 9

Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,611

Underlying: Common Stock · 28,611 shares

Expires 2030-04-30

F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F11 · derivative.exercise_date: 9,537 shares underlying the option are fully vested. The remaining shares vest and become exercisable in two equal installments on May 1, 2022 and May 1, 2023.

SEC source: 0000899243-21-022199 · doc4.xml · derivative · entry 8

Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,606

Underlying: Common Stock · 19,606 shares

Expires 2029-05-02

F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F10 · derivative.exercise_date: 13,071 shares underlying the option are fully vested. The remaining shares vest and become exercisable on May 3, 2022.

SEC source: 0000899243-21-022199 · doc4.xml · derivative · entry 7

Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,015

Underlying: Common Stock · 11,015 shares

Expires 2023-12-31

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock.

F6 · kind: In connection with the Separation, each outstanding Merck performance stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck performance stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F8 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in a single installment on December 31, 2023.

SEC source: 0000899243-21-022199 · doc4.xml · derivative · entry 6

Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,125

Underlying: Common Stock · 5,125 shares

Expires 2022-12-31

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock.

F6 · kind: In connection with the Separation, each outstanding Merck performance stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck performance stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F7 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in a single installment on December 31, 2022.

SEC source: 0000899243-21-022199 · doc4.xml · derivative · entry 5

Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,794

Underlying: Common Stock · 4,794 shares

Expires 2021-12-31

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock.

F6 · kind: In connection with the Separation, each outstanding Merck performance stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck performance stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

SEC source: 0000899243-21-022199 · doc4.xml · derivative · entry 4

Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,310

Underlying: Common Stock · 8,310 shares

Expires 2024-05-04

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock.

F3 · kind: In connection with the Separation, each outstanding Merck restricted stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck restricted stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F5 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in three equal installments on May 4, 2022, May 4, 2023 and May 4, 2024.

SEC source: 0000899243-21-022199 · doc4.xml · derivative · entry 3

Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,440

Underlying: Common Stock · 2,440 shares

Expires 2023-05-01

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock.

F3 · kind: In connection with the Separation, each outstanding Merck restricted stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck restricted stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F4 · derivative.exercise_date: These restricted stock units vest and are distributed as shares of Organon common stock in two equal installments on May 1, 2022 and May 1, 2023.

SEC source: 0000899243-21-022199 · doc4.xml · derivative · entry 2

Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 871

Underlying: Common Stock · 871 shares

Expires 2022-05-03

F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Organon common stock.

F3 · kind: In connection with the Separation, each outstanding Merck restricted stock unit award was converted into a restricted stock unit award denominated in shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of underlying shares was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck restricted stock unit award. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

SEC source: 0000899243-21-022192 · doc4.xml · derivative · entry 15

Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,764

Underlying: Common Stock · 83,764 shares

Expires 2031-05-03

F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F12 · derivative.exercise_date: The option vests and becomes exercisable in three equal installments on May 4, 2022, May 4, 2023 and May 4, 2024.

SEC source: 0000899243-21-022192 · doc4.xml · derivative · entry 14

Morrissey Joseph T. Jr. · CIK 0001859805 · Head of Manufacturing

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,967

Underlying: Common Stock · 34,967 shares

Expires 2030-04-30

F9 · kind: In connection with the Separation, each outstanding Merck stock option was converted into an award of options to purchase shares of Organon common stock pursuant to the terms of the employee matters agreement between Merck and Organon. The number of shares and exercise price of each option award was adjusted in a manner intended to preserve the aggregate intrinsic value of the original Merck stock option. The value reflects Organon's best estimate of the numbers using the currently available information and may be subject to adjustment following finalization of calculations.

F11 · derivative.exercise_date: 11,654 shares underlying the option are fully vested. The remaining shares vest and become exercisable in two equal installments on May 1, 2022 and May 1, 2023.